User login
Medical Education Library
A Best Practices Supplement to Skin & Allergy News®. This supplement was sponsored by Valeant Pharmaceuticals North America LLC.
- Introduction
- Treatment with ELIDEL ® (pimecrolimus) Cream 1%
- IMPORTANT SAFETY INFORMATION
Faculty/Faculty Disclosure
Dr. Adelaide A. Hebert, MD
University of Texas Medical School at Houston
Houston, Texas
Dr. Hebert reported that she has served as a consultant and speaker for Astellas Pharma US, Inc.; Novartis Pharmaceuticals Corporation; and Valeant Pharmaceuticals, North America, LLC. Her employer, the University of Texas Health Sciences Center-Houston has received grant funding for research conducted by Dr. Hebert for Astellas and Novartis.
Copyright © by Frontline Medical Communications Inc.
Medical Education Library
A Best Practices Supplement to Skin & Allergy News®. This supplement was sponsored by Valeant Pharmaceuticals North America LLC.
- Introduction
- Treatment with ELIDEL ® (pimecrolimus) Cream 1%
- IMPORTANT SAFETY INFORMATION
Faculty/Faculty Disclosure
Dr. Adelaide A. Hebert, MD
University of Texas Medical School at Houston
Houston, Texas
Dr. Hebert reported that she has served as a consultant and speaker for Astellas Pharma US, Inc.; Novartis Pharmaceuticals Corporation; and Valeant Pharmaceuticals, North America, LLC. Her employer, the University of Texas Health Sciences Center-Houston has received grant funding for research conducted by Dr. Hebert for Astellas and Novartis.
Copyright © by Frontline Medical Communications Inc.
Medical Education Library
A Best Practices Supplement to Skin & Allergy News®. This supplement was sponsored by Valeant Pharmaceuticals North America LLC.
- Introduction
- Treatment with ELIDEL ® (pimecrolimus) Cream 1%
- IMPORTANT SAFETY INFORMATION
Faculty/Faculty Disclosure
Dr. Adelaide A. Hebert, MD
University of Texas Medical School at Houston
Houston, Texas
Dr. Hebert reported that she has served as a consultant and speaker for Astellas Pharma US, Inc.; Novartis Pharmaceuticals Corporation; and Valeant Pharmaceuticals, North America, LLC. Her employer, the University of Texas Health Sciences Center-Houston has received grant funding for research conducted by Dr. Hebert for Astellas and Novartis.
Copyright © by Frontline Medical Communications Inc.
